“We are also happy to announce that Gufic has secured DCGI approval for the manufacturing and marketing of Dalbavancin and we are the first Company to receive such approval in India. Trial for sepsis involving Immunocin Alpha have completed successfully and we anticipate the DGCI approval by Q3 of this year. On the Ferticare business front, the introduction of an enhancing human menopausal gonadotropin marks a significant step in boosting the success rates of IVF cycles. This advanced formula aims to reduce the chances of cycle failure. Gufic’s strategic investment in developing recombinant alternatives to critical hormone used in infertility treatment positions us to be self-reliant. The development work for these alternatives is well underway and we anticipate product-readiness within 15 to 16 months.”
-Ami Shah, Company Secretary & Compliance Officer
Stock Data
| Ticker | GUFICBIO |
| Industry | Pharmaceuticals |
| Exchange | NSE |
Share Price
| Last 5 Days | -5% |
| Last 1 Month | -6.8% |
| Last 6 Months | 40.9% |
Business Basics
Gufic BioSciences Limited, a prominent pharmaceutical company based in India, operates with a commitment to scientific research, innovation, and the development of pharmaceutical and healthcare solutions. The company’s business fundamentals are grounded in its diversified portfolio of pharmaceuticals, active pharmaceutical ingredients (APIs), and healthcare products, catering to both domestic and international markets. At the core of Gufic BioSciences’ business strategy is its expertise in pharmaceuticals. The company manufactures and markets a wide range of pharmaceutical formulations, including tablets, capsules, injections, and topical products. These pharmaceuticals cover various therapeutic categories, contributing to healthcare solutions for a broad spectrum of medical conditions and diseases.
Gufic’s focus on innovation extends to introducing niche and specialized pharmaceutical products that address unmet medical needs in diverse therapeutic areas. The company’s international presence and commitment to exports underscore its focus on expanding its footprint in the global pharmaceutical market. By exporting APIs and finished pharmaceutical products to various countries, Gufic BioSciences contributes to the global healthcare industry while enhancing its global reputation.
Q1 FY24 Financial Performance
Gufic BioSciences reported Revenues for Q1FY24 of ₹195 Crores up from ₹165 Crore year on year, a rise of 18.18%. The consolidated Net Profit for this quarter was ₹21 Crore. The Earnings per Share is ₹2.13, down 1.84% from ₹2.17 in the same quarter of the previous year.
Indore Facility Poised to Go Live
In a significant development, the Indore Facility is gearing up to go live with a host of promising advancements in research and development (R&D). The facility’s progress is set to expedite the commercialization of innovative molecules, with a validation milestone targeted for completion by September 2023. The substantial investment in research and development at the Indore facility is yielding highly promising results. These advancements are significantly enhancing the facility’s product pipeline, setting the stage for potential breakthroughs in the world of science and technology.
Efforts are in full swing to reduce the time-to-market, ensuring a swift and efficient process for the commercialization of innovative molecules. This focus on efficiency is set to transform the landscape of product development, ensuring that groundbreaking discoveries reach consumers in record time.
Gufic Announces Major Developments in Critical Care Division
In a significant turn of events, Gufic Pharmaceuticals’ Critical Care Division is experiencing a remarkable resurgence in its portfolio. After a period of subdued performance linked to post-COVID inventory build-up, the division is now witnessing robust growth across key molecules. The Sparsh division, a part of Gufic, has achieved a major milestone by establishing a presence in over 6,000 hospitals out of 8,357 hospitals across India, with the launch of 92 molecules. This comprehensive market mapping effort bodes well for the company’s market penetration.
In a groundbreaking achievement, Gufic has received approval from the Drug Controller General of India (DCGI) for the manufacturing and marketing of Dalbavancin, positioning the company as the first in India to secure such approval. Collaborating with two leading Contract Manufacturing Organizations (CMOs), Gufic is gearing up to launch this product for the first time in the country. Furthermore, Gufic’s brand “Cavim,” a combination of Ceftazidime and Avibactam, launched in the fourth quarter of FY23, has garnered recognition as one of the top 20 new product launches, according to IQVIA. This achievement underscores the company’s dedication to impactful innovations.
Trials for Immunocin-Alpha, a critical care drug for sepsis, have successfully concluded. Gufic anticipates DCGI approval by Q3, demonstrating the company’s commitment to advancing critical care treatments. In a strategic move, Gufic Pharmaceuticals is poised to enter the rapidly expanding Total Parenteral Nutrition market. The company’s ongoing product development efforts encompass Single Chamber and Multi-Chamber bags, aligning with evolving healthcare demands.
Update On R&D
Gufic Pharmaceuticals is making significant strides in research and development, paving the way for in-house critical Active Pharmaceutical Ingredient (API) manufacturing. This strategic endeavor aligns seamlessly with the company’s broader vision of internalizing API production, emphasizing self-reliance and robust supply chains. The creation of Innovative Dual Chamber Syringes is groundbreaking development in drug delivery systems. These syringes offer streamlined reconstitution, precise dosing, and sustained sterility, bridging the gap from plant to patient.
In the realm of API research and development, Gufic’s Navsari facility has achieved noteworthy milestones in therapeutic categories such as Antifungal, Anticoagulant, Tetracycline Antibiotics, Progestin, Beta 3 Adrenergic Agonists, Antidiabetic, and Cyclopeptide Hormones. These advancements align with the company’s strategic plan, propelling them toward pioneering breakthroughs in critical therapeutic areas.